x
CME-Tagline

Hitting the Target with IL-23 Inhibitors in Psoriatic Arthritis

CMEO Webcast

Live Webcast: Wednesday, November 4, 2020
6:30 PM - 8:00 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, November 4, 2021

Faculty


Atul A. Deodhar, MD, MRCP, DNB, FACR, FACP Atul A. Deodhar, MD, MRCP, DNB, FACR, FACP (Moderator)
Professor of Medicine
Medical Director, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, OR

Philip J. Mease, MD Philip J. Mease, MD 
Director, Rheumatology Clinical Research
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA

Christopher T. Ritchlin, MD, MPH Christopher T. Ritchlin, MD, MPH 
Professor of Medicine
University of Rochester School of Medicine & Dentistry
Chief, Division of Allergy, Immunology & Rheumatology
University of Rochester Medical Center
Rochester, NY

Statement of Need

Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease with a significant impact on quality of life and functional ability. Despite the data showing the overall impact of PsA, delays in diagnosis are common, which can lead to long-term joint damage and functional disability.

In this CME Outfitters Live and OnDemand activity, expert faculty will focus on assessment, treatment, and management strategies to provide patients with the best treatment aligned with evolving evidence and expert recommendations.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Decrease diagnostic delays through better identification of signs and symptoms of PsA.
  • Apply key clinical efficacy and safety data for IL-23 inhibitors to treatment decisions in patients with PsA.
  • Collaborate with patients to optimize treatment regimens across the health continuum.

The following learning objectives pertain only to those requesting CNE credit:

  • Describe ways to decrease diagnostic delays through better identification of signs and symptoms of PsA.
  • Identify key clinical efficacy and safety data for IL-23 inhibitors for treatment decisions in patients with PsA.
  • Summarize how to collaborate with patients to optimize treatment regimens across the health care continuum.

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

Rheumatologists, dermatologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-20-112-L01-P
Enduring: 0376-0000-20-112-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Deodhar reports that he receives research grants from AbbVie Inc.; Eli Lilly and Company; GlaxoSmithKline; Novartis; Pfizer Inc.; and UCB, Inc. He is a consultant or on advisory boards for AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim; Celgene Corporation; Eli Lilly and Company; Galapagos, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis; Pfizer Inc.; and UCB, Inc.

Dr. Mease reports he receives grants from AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc. He is a consultant for AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc. He is on the speakers bureau for AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc.

Dr. Ritchlin reports he receives grants from AbbVie Inc.; Amgen Inc.; and UCB, Inc. He is a consultant for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc.

Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TV-118-110420-01